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Abstract
Background: Awareness of the diagnosis or related changes in functioning varies in people with dementia (PwD), with impli-
cations for the well-being of PwD and their carers. Measuring awareness in a clinical setting could facilitate tailored support and
optimize involvement in personal health and care decisions. This scoping review aimed to identify validated methods of assessing
awareness in dementia and appraise their clinical utility. Method: A systematic search was conducted of English-language pub-
lications that measured awareness in PwD, in 6 electronic databases. Search terms included dement*, Alzheimer*, Pick disease,
and awareness, unawareness, anosognosia, insight, denial, metacognit*, or discrepanc*. Results: We screened 30,634 articles,
finding 345 articles that met our inclusion criteria. We identified 76 measures, most commonly using a discrepancy questionnaire
comparing evaluations of function by PwD and an informant. There were 30 awareness measures developed and validated for use
in dementia populations but few designed for general clinical use. Conclusions: Although we found a range of clinical indications
for measuring awareness, there were few studies investigating clinical applications and few tools designed for clinical purposes.
Further investigation and development of a person-centered tool could facilitate health and care choices in mild-to-moderate
dementia.
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Introduction
Background
A diagnosis of dementia, or major neurocognitive disorder,
requires evidence of functional impairment alongside cognitive
decline.1,2 People with dementia (PwD) vary in their awareness
of the diagnosis3 or of their decline in cognitive and functional
abilities.4-7 The frequency of impaired awareness is difficult to
affirm as it depends on how and in whom it is measured,4,5 and
estimates range from 20% to 81%. A study using a multidimen-
sional assessment in people with mild-to-moderate dementia
found 14% had greater awareness and 41% had limited aware-
ness, with the remainder classed as moderately aware.8 This
has consequences for the well-being of PwD, with reduced
awareness shown to predict risk of unsafe behavior, hospital
admission, and institutionalization,9,10 and has implications for
care provision and planning. For family members or close
friends who provide unpaid support (for convenience, we will
refer to these as “carers”), lack of awareness of difficulties with
functioning on the part of PwD is associated with increased
stress8,11,12 and poorer perceived relationship quality.13 This in
turn may indirectly reduce the quality of life for PwD14 and
could contribute to a breakdown of home-care arrangements. A
small proportion of PwD retain high levels of awareness of
their condition, and this can be associated with dysthymia and
anxiety15 and may infer a need for increased support around the
time of diagnosis.16 Furthermore, some PwD underestimate
their abilities particularly in the area of socioemotional func-
tioning.17 This might reflect the more complicated appraisal
needed by PwD or informants to rate socioemotional behavior,
which may be more influenced by personal values or beliefs.
Alternatively, it may represent an awareness of changes, and
perhaps in the context of the stigma associated with dementia,
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result in an overly pessimistic view of abilities. This could lead
to unnecessary avoidance of beneficial activities.
Measuring awareness effectively in a clinical setting could
help to build a more accurate picture of an individual’s expe-
rience, resulting in personalized care and activity planning.
Benefits could include improved communication, for example,
by establishing whether the individual is aware of the diagnosis
of dementia as a starting point, and enhanced involvement in
decisions around personal health care or self-management.
Higher awareness may mean that an individual is able to make
use of adaptive strategies such as memory aids to continue
living at home independently and managing own medication,
and awareness measurement could be useful in assessing out-
comes of rehabilitative interventions. Awareness has been
shown to be an important independent factor influencing capac-
ity to make decisions particularly in the mild-to-moderate
stages of dementia, where people with lower awareness are less
likely to be judged to have capacity, for example, in decisions
around medication,18-20 or when addressing legal matters such
as wills and advance directives.21 Understanding an individu-
al’s awareness profile could also be helpful for discussions
around health and care needs on occasions when a person with
dementia attends the clinic unaccompanied.
Nevertheless, awareness is a complex phenomenon, as
demonstrated by the range of models developed to explore the
related concepts.22-25 Different approaches have been taken to
measure awareness, using different terminology to reflect the
slightly different concepts. Terms include “anosognosia,” used
initially to describe lack of awareness of a specific neurological
deficit26 but applied since then to loss of awareness in demen-
tia5,27; “insight,” originally from psychiatry regarding aware-
ness of a condition or symptoms28; “denial,” referring to
largely psychodynamic factors that affect expression of aware-
ness29; and “metacognition,” describing self-awareness of cog-
nitive ability.24 Awareness can be considered to operate at
different “levels,” ranging from simple sensory registration,
to online monitoring of performance, evaluating specific situa-
tions, and the higher level of meta-representation of one’s sit-
uation and the impact on others.25,30 It can also be implied
indirectly through observations of behavior if not explicitly
stated.31,32
Awareness should be understood as having an “object,” for
example, awareness of specific cognitive deficits such as mem-
ory problems or awareness of changes in behavior such as
social functioning. Since the degree of loss of awareness can
vary in any individual between objects, it is helpful to specify
the object that is being considered either clinically or in
research.17,33 For clinical applications, the object studied
would determine the usefulness of an assessment. While aware-
ness of cognitive deficits such as memory impairment is com-
monly studied, awareness of difficulties with activities of daily
living (ADLs) may be more directly relevant to determine
where help is needed, although there is an overlap between
cognitive difficulties and the ability to carry out everyday
tasks.34,35 Additionally, considering the individual objects of
awareness helps to clarify the correlates and potential
consequences. For example, impaired awareness of dangerous
behavior has been associated with hospital admission and resi-
dential care placement9 and physical health awareness has
implications for managing other health problems. Impaired
functional awareness has been associated with developing
frailty36 and measurement of awareness could contribute to
frailty assessment.
Building on a model of the cognitive processes behind
awareness,37,38 a wider approach incorporates psychosocial
factors, as well as the concepts of levels and objects of aware-
ness,22 and has helped to explain the heterogeneity of results
from earlier studies where these issues were not specified,17,39
Other studies have clarified the influence of cultural factors on
expressed awareness4 and the importance of social opportuni-
ties to demonstrate awareness.30,40,41 A comprehensive biop-
sychosocial model assists understanding by describing
awareness as a sequence of registering and reacting to change,
where responses are influenced by the social environment,
individual features of past history, personality and coping
styles, as well as the degree of neurocognitive impairment.6,22
From this model, the term “awareness” is defined here as “the
ability to hold a reasonable or realistic perception or appraisal
of, and/or respond accordingly to, a given aspect of one’s envi-
ronment, situation, functioning, or performance.”30,p20 This
broad definition permits consideration of awareness, either
retained or reduced, across different objects and levels, and
either explicitly or implicitly demonstrated.
Methods of measuring awareness include ratings or judg-
ments from clinician interviews, or use of questionnaires that
compare the self-evaluation of ability by PwD with an infor-
mant evaluation, using the discrepancy between them as an
index of awareness. A further method utilizes the discrepancy
between self-ratings by PwD and their performance on an
objective task. There are also activity-based qualitative and
observational methods described in the research literature.42
There are known limitations to each type of method, which
may be nonspecific or restricted in terms of the object and level
of awareness assessed, or at risk of bias from use of subjective
ratings.43 The majority of methods have been developed for
research purposes, rather than as clinical tools for assessing
awareness in everyday living, perhaps because in clinical prac-
tice, awareness tends to be appraised informally or
nonspecifically.
Objectives
We wanted to explore the availability of methods that could be
used to measure awareness in a clinical setting. Expectations
for an ideal clinical tool might include the following features: it
should assess objects of awareness that are relevant to everyday
situations; it should be brief and simple enough to administer in
clinic with basic staff training, to encourage widespread use;
and it should be developed with, and validated for, PwD to
ensure relevance and acceptability. To investigate and compare
the available methods, we planned a review showing the
approaches taken across different settings and with people at
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different stages of dementia and with different dementia diag-
noses. Previous reviews date from 2005 or earlier,42,43 or cover
different patient populations44 and to our knowledge there are no
recent English-language systematic or scoping reviews of these
methods, relating specifically to dementia. We, therefore,
describe a scoping review, which aimed to provide a comprehen-
sive overview of the available methods of measuring awareness
in PwD. This enables identification of validated measures and
further appraisal of the components for potential clinical use.
We chose a scoping methodology as it combines rigor with flex-
ibility and allows inclusion of quantitative and qualitative stud-
ies, as well as case studies, because we wanted to demonstrate
current clinical and research practice for assessing awareness.
Methods
Study Design
This scoping review focused on the question: “What methods
and measures are used to assess awareness in PwD, and what
are the characteristics and utility of each method?” The review
is based on the Arksey and O’Malley framework45 with addi-
tional guidance from later publications.46,47 This involves a
systematic search of a broad range of literature leading to an
overview or map of the relevant research with a descriptive
analysis.48 Our previously published protocol49 used guidance
from Preferred Reporting Items for Systematic Reviews and
Meta-analysis-Protocol (PRISMA-P);50,51 and this report fol-
lows the PRISMA extension for scoping review guidelines.52
Search Strategy
A search was made on February 4, 2019, of the electronic
bibliographic databases PubMed, Embase, PsycInfo, Cumula-
tive Index to Nursing and Allied Health Literature complete,
Web of Science Core collection, and Cochrane Library for
relevant peer-reviewed, published literature. Search terms used
were (dement* OR Alzheimer* OR “Pick’s disease”) AND
(aware* OR unaware* OR anosognosia OR insight OR denial
OR metacognit* OR discrepanc*), with unlimited date range
and no language restriction (see protocol for electronic search
strategy). Duplicate records were removed. Titles and abstracts
were screened by 2 independent researchers for removal of
inappropriate articles, with 98% agreement. Full texts of the
remaining articles were examined according to eligibility cri-
teria, as outlined below and detailed in our published proto-
col,49 to produce a list of included articles. A second researcher
screened a 10% sample of the full-text articles for selection,
reaching 92% agreement. Differences were discussed and
resolved by consultation with a third senior researcher. Mem-
bers of the review team were not involved in decisions about
the inclusion of those studies which they had authored.
Study Selection
Population. We included studies that measured awareness (or
equivalent term) in people with a clinical diagnosis of dementia
of any type and all degrees of severity. Settings were not
restricted and included community, outpatient, inpatient, and
residential settings. There were no limitations of age, gender, or
ethnicity. Studies with mixed populations were included if 50%
or more of the participants had a clinical diagnosis of dementia
and these data were separately identifiable.
Concepts. We included studies that measured awareness in PwD
using either standardized tools or new methods devised for a
specific study, where awareness was measured as a global con-
struct or in relation to specific objects or domains such as
awareness of memory function, socioemotional functioning,
or everyday functional ability.
Context. Selected studies were English-language publications,
where full text was available. We included quantitative, mixed
method and qualitative studies, and case studies to scope a
broad range of awareness research.
Exclusion criteria. We excluded studies that primarily studied
mild cognitive impairment or non-dementia diagnoses, along
with non-original or non-peer-reviewed material or where data
from dementia participants were not separately identifiable.
Studies that did not measure the awareness construct were
excluded. Exclusion decisions and characteristics of excluded
studies were recorded according to PRISMA guidelines.
Data Extraction and Mapping Results
For each included study, standard information was recorded
and charted according to key characteristics. A second
reviewer checked data extraction for the first 20 articles, and
discussions enabled refinement of the data extraction process.
Data items included name of study or grant number, study
design, geographical region of study derived from country
(assumed from author affiliation if otherwise unclear), setting,
sample size, type and severity of dementia based on mean
Mini-Mental State Examination,53 Clinical Dementia Rating54
or verbal report where available, age and gender of partici-
pants, the type of informant, the specific measures, and the
type of method used. The object of awareness was recorded
where stated, or otherwise inferred from the methodology
reported. Method of data analysis was included for qualitative
studies. Details of specific measures included how the aware-
ness rating was made, the scoring and number of items where
relevant, and whether the measure was intended for clinical
use. Validation data were reported if there was evidence of any
evaluation of validity, reliability, or internal consistency.
Collating, Summarizing, and Reporting Results
The results have been tabulated to demonstrate the full
scope of included articles, to identify the key named and
validated measures, and to appraise the characteristics and
clinical utility of these measures. The range of methods
used and the objects studied have been mapped
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diagrammatically. We shared the findings with expert clin-
icians, consulting in particular regarding the clinical impli-
cations. Results will be reported regarding the included
articles and the types of methods and objects assessed, fol-
lowed by the specific measures identified.
Results
Search Findings
Exclusion decisions are documented in the PRISMA flow dia-
gram (see Figure 1). Of the 30,634 records identified in the
search, 345 articles were included in the review: 325 quantita-
tive articles including 4 case studies, and 20 qualitative articles.
There were 39 articles reporting longitudinal studies. The influ-
ence of awareness on the outcome of or responses to interven-
tions was investigated in 7 quantitative and 4 qualitative
studies. The majority of research was conducted in Europe or
North America. Details of quantitative articles and case studies
are recorded in Supplementary Table 1a and b, respectively.
Qualitative studies are summarized in Supplementary Table 2.
Articles excluded at full-text screening, with exclusion reasons,
are listed in Supplementary Table 3.
Demographic Characteristics of Participants
Most of the participants were community dwelling and
recruited from outpatient clinics or memory clinics. The major-
ity of the articles studied people with mild-to-moderate
Records idenfied through database 
searching 
(n = 30,634)
Records aer duplicates removed 
(n = 14,554)
Records screened 
(n = 14,554)
Records excluded 
(n = 14,035)
Full-text arcles assessed 
for eligibility 
(n = 519)
Full-text arcles excluded 
(n = 174):
Non-original
(n = 24)
Full-text not in 
English (n = 15)
Conference 
abstracts (n = 5)
Errata non-
significant (n = 4)
Not demena
(n = 19)
Data for demena 
not separately 
idenfiable
(n = 20)
Not measured 
awareness 
(n = 77)
Full-text not readily 
available (n = 10)
Studies included in
qualitave synthesis 
(n = 345)
Figure 1. Preferred Reporting Items for Systematic Reviews and
Meta-analysis-Protocol flow diagram.
Table 1. Demographic Characteristics of Participants in the Included
Studies.
Characteristic Details
Region of study
(number of articles)
Europe 143
North America 116
South America 41
Asia 32
Oceania 12
South America and Asia 2
South America and Oceania 1
Age in years. Sample means range
(age range)
57.3-85.5 (25-96a)
Gender (% articles with >50%
females recorded)
66
Dementia severityb where reported, n (%)
Mild-to-moderate 280 (81.2)
Severe 6 (1.7)
Mixed 29 (8.4)
Dementia type where reported, n (%)
AD studied alone
with other diagnoses
216 (62.6)
93 (26.9)
VaD studied alone
with other diagnoses
3 (0.9)
63 (18.2)
FTD studied alone 11 (3.2)
with other diagnoses 51 (14.7)
Mixed AD/VaD studied alone 0
with other diagnoses 34 (9.8)
Other DLB 17
PDD 9
Alcohol or substance related 6
ALS 1
HDD 3
CBS 3
PSP 1
ADC 1
Young onset dementia 7
Type of informant
(no. articles reporting)
Spouse/partner 75
Adult child of PwD 67
Other relative 45
Friends 19
Abbreviations: AD, Alzheimer disease; ADC, AIDS dementia complex; ALS,
amyotrophic lateral sclerosis; CBS, corticobasal syndrome; DLB, dementia with
Lewy bodies; FTD, frontotemporal dementia; HDD, Huntington disease
dementia; PDD, Parkinson disease dementia; PSP, progressive supranuclear
palsy; PwD, person with dementia; VaD, vascular dementia.
aGregory and Gibbs (2002), otherwise range 49 to 96.
bSeverity defined as mild-to-moderate if Clinical Dementia Rating 2, Mini-
Mental State Examination 10, Global Deterioration Scale 3 to 5, or
described verbally as mild or moderate; severe defined as Clinical Dementia
Rating¼ 3, or Mini-Mental State Examination <10, Global Deterioration Scale
>5, or defined verbally as severe.
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dementia, and the most frequent diagnosis was Alzheimer dis-
ease (AD). For further details, see Table 1.
Methods Shown in Articles
Quantitative Articles (Including Case Studies)
We found 325 articles that investigated awareness quantita-
tively, 4 of which were case studies. Broadly categorized, the
quantitative methods comprise questionnaires eliciting discre-
pancies between self- and informant ratings (used in 55% of
articles), discrepancies between self-ratings and objective mea-
surement of performance (24%), and ratings by a clinician or
researcher based on an interview (37%). This latter category
includes in-depth unstructured interviews as well as brief clin-
ical ratings based on responses to a single question or a few
questions. Informants were usually informal carers, typically a
female relative. Other variations of these methods were used in
47 articles; see Figure 2 for details. Mixed methods were used
in 8 of these studies and the qualitative methods employed are
recorded in Figure 2.
The discrepancy questionnaires included non-validated
methods where a questionnaire validated to assess ability of
PwD was supplemented by a parallel version of the question-
naire for an informant, creating a discrepancy score as an indi-
cation of awareness (see Figure 2). The most frequently utilized
measure for this purpose was the Physical Self-Maintenance
Scale/Instrumental Activities of Daily Living scale55 used in 9
articles to study awareness of ADL. Some studies used self-
rating scales of cognitive function, for example, Everyday
Memory Questionnaire56 used in 6 articles, or Cognitive Dif-
ficulties Scale57 in 6 articles, which alone are subjective mea-
sures of cognitive complaint; however in these articles, they
were used to produce a discrepancy with informant ratings or
with objective performance as an indicator of awareness. Addi-
tional nonstandardized approaches are seen in 59 articles mea-
suring objective performance compared to self-ratings,
including experimental metamemory methods. Eighty-five
articles employed more than one measure, with some using
up to 6 measures (3 articles); see Figure 2 for more details.
Qualitative Articles
We found 20 articles that investigated awareness qualitatively.
The most common qualitative method of assessing awareness
was by interview (65% of qualitative articles) with varying
degrees of structure, mostly involving analysis of an audio
transcript. Observational techniques were used in 8 (40%) arti-
cles. Group session transcripts were analyzed in 2 articles, and
family carers were involved in 8 articles either with a sepa-
rately recorded interview or video-recordings of family inter-
actions. Three articles used more than 1 qualitative method to
gather data and 3 used an additional quantitative method. A
range of methods was used to analyze the data; see Figure 2 for
further detail.
Objects of Awareness
The most commonly examined object was cognition (in 80% of
articles), typically memory function. Functional ability was
assessed in 44% of articles, that is, basic and/or instrumental
ADL. Behavioral domains were assessed in 42% of articles
with most looking at general awareness of social and emotional
functioning; some were more specific to awareness of a psy-
chiatric symptom. Other main objects were awareness of phys-
ical symptoms (19%) and awareness of the diagnosis of
dementia (27%). Nearly half of the articles (170 of 345)
focused on a single object of awareness; see Figure 2 for more
details.
Identified Measures
There were 76 named or standardized measures (see Supple-
mentary Table 4a-d for full names and abbreviations used, and
references), of which 30 presented some form of validation
data (see Supplementary Table 4a). Some measures were
developed for PwD but lack reported validation data (see Sup-
plementary Table 4b). Other well-established measures were
developed in populations other than dementia, though 3 of
these have subsequently been validated for dementia (see Sup-
plementary Table 4c). We also found single-item measures
used to assess awareness, taken from clinically developed
assessment tools (see Supplementary Table 4d). Some of these
“insight items” were taken from scales designed for a broader
assessment of dementia (n ¼ 6), from scales for assessing
mental illness (n ¼ 4), or from dementia diagnostic scales (n
¼ 2). While they were treated as single items in an overall
scale, some of these items required responses to more than one
question or information from more than 1 source to form the
score of the item. In total, 206 articles used at least 1 standar-
dized measure, and 160 of these used a validated measure
developed for dementia.
Validated Measures Designed to Measure
Awareness in PwD
We further investigated the 30 measures that reported valida-
tion data (see Supplementary Table 5a-d). Of the validated
measures, the most common method was the discrepancy
questionnaire (see Supplementary Table 5a), with the most
frequently employed being the anosognosia questionnaire-
Dementia (AQ-D). Clinician interview ratings were the next
most common type (see Supplementary Table 5b), with the
Reed rating the most frequently used. Methods which combine
self-evaluation with informant rating and objective task perfor-
mance formed just 3 measures (see Supplementary Table 5c),
of these the most frequently used was the Memory Awareness
Rating Scale (MARS). Nine measures used other variations on
these methods (see Supplementary Table 5d). Mixed objects of
awareness were assessed by most of these measures, followed
by memory only, while 2 tools looked at very specific func-
tional objects (see section 3.7 below for more detail). There
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345 articles
Methods
Quantitative
methods
D-Q
  (Total k=180)
 incl. quant k=178 +
m-m k=2
Includes use of parallel
non-validated
questionnaires (k=31)
Self/Obj
 (Total k=77)
 incl. quant k=76 +
m-m k=1
 Includes  post-diction
rating (k=50)
C/R 
(k=118)
Other
  (k=47)
 Explicit awareness includes:
Informant rating only (k=9)
Self-rating only (k=7)
Self-report of physical
symptom/objective physiological
measurement (k=4)
Error detection test: observed
responses (k=3), physiological
responses (k=2)
Observations: quantitative (k=1)
Vignettes (k=2)
Variations of D-Q using dissimilar
scales PwD/informant (K=3)
Variations of C/R (k=3), using VR
(k=1)
Other combined variants (k=9)
 Non-explicit awareness
 comparing   self-report with:
Physiological response (k=1)
Facial expression (k=1)
Emotional Stroop processing time
(k=1)
Qualitative
methods
   Interview (Total k=15)
Unstructured (k=6)
Structured (k=9) incl. Qual k=7 
+ m-m k=2
   Observational (Total k=13)
Video recording of care (k=1)
Video of family interaction (k=3)
Field notes (k=8) incl qual k=3 + 
m-m k=5
Structured questionnaire to
record observations (k=1)
    Other: (m-m k=1)
Responses to prompt questions,
transcripts coded 
Sentence completion 
   Data analysis
Thematic analysis (k=3)
Content analysis (k=4)
Grounded theory (k=2)
IPA (k=4)
EPP (k=2)
Analytic induction (k=1)
MAPE framework (k=3)
Case analysis (k=2)
Unclear (k=8)
Objects
Cognitive
  (k=275)
Sole object cognition
(k=106), mainly
memory. Others
include executive
function, visuo-spatial
skill, language
Functional
(k=152)
Sole object  functional
(k=12), bADL and
iADL.
Others include financial
skills, driving ability,
medication
management and
adherence,
topographical
disorientation.
Behavioural
(k=145
Sole object behavioural
(k=27). Includes
awareness of
psychiatric symptoms:
apathy, stereotypy,
disinhibition,
mood/depression,
personality change,
empathy, social eating
behaviour,
walking/wandering,
need for help.
Physical 
(k=67)
Sole object physical
(k=7). Includes motor
function, general health,
limb praxis, vision,
sphincter control,
olfactory function,
heartbeat
detection/interoception,
other sensory stimuli 
Condition 
(k=94)
Sole object
condition or
diagnosis (k=18)
Figure 2. Map of methods and objects. bADL indicates basic activities of daily living; C/R, clinician rating; D-Q, discrepancy questionnaire; EPP,
empirical phenomenological psychological; iADL, instrumental activities of daily living; IPA, interpretative phenomenological analysis; k, number
of articles; MAPE, markers of assimilation of problematic experiences; m-m, mixed-methods article; PwD, person with dementia; self/obj, self-
rating/objective performance; VR virtual reality.
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was no apparent pattern in choice of measure according to the
type of dementia. No gold standard was evident. The validated
tools used in the intervention studies were MARS, clinical
insight rating scale (CIRS), self-consciousness questionnaire
(SC-Q), and Reed. The only validated tool used among the 4
case studies was the assessment scale of psychosocial impact of
the diagnosis of Dementia (ASPIDD).
Clinical Utility of Validated Measures
Regarding brevity, the questionnaires employed to produce a
discrepancy rating varied considerably in number of items and
estimated time to complete (see Supplementary Table 5a). The
clinician rating measures generally had fewer items, typically
with 3 or 4 opening questions, though the duration of interview
required is unclear (see Supplementary Table 5b). The com-
bined methods with both questionnaire items and objective
tasks were characteristically longer (see Supplementary Table
5c). For scoring, one measure used a categorical rating, and 29
used a scale, of which 4 employed cutoff scores to dichotomize
awareness. In terms of accessibility, questionnaire measures
placed different requirements on participants; the majority
asked PwD to rate abilities or problems on a Likert-style scale
or by frequency of occurrence (n ¼ 13), or to endorse items or
symptoms with yes/no responses (n ¼ 6). Some rate function
compared to an average person or as a self-comparison over the
past 3/5/10 years.
Six of the validated measures were designed to be used in
clinical settings (see Table 2). These include 2 measures
designed with a specific purpose: assessing awareness of finan-
cial skills (Measure of Awareness of Financial Skills [MAFS])
or assessing awareness of navigational ability (Questionnaire
for Everyday Navigational Ability [QuENA]). Only 1 measure
was specifically designed for use in severe dementia to support
Table 2. Validated Tools With Potential Clinical Use.
Name of tool (method type) Potential benefits Possible limitations
AAQ (discrepancy questionnaire) Mixed objects. Brief (9 items), easy to administer,
abridged from well-established measure.
Designed to diagnose lack of awareness in a
clinical context.
Dependent on reliability of informant ratings.
Focuses on lack of awareness of problems, not
awareness of abilities.
AwareCare (observational) Designed for severe dementia. Can be used to
support care provision or staff training. Any
sensory object.
Staff need experience to use as assessment tool.
Depends on length of time available for
observation.
DDS (other: discrepancy
questionnaire self/informant þ
discrepancy questionnaire self/
clinician)
Mixed objects. Uses 2 informants and looks for
convergence of ratings.
Use of 2 informants increases time needed.
Unclear how 2 scores can be combined to use as
single index.
DQ (discrepancy questionnaire) Mixed objects. Medium length (16 items) Mixed reports of reliability of informant rating
when compared to objective tests.
MAFS (combined: discrepancy
questionnaire self/informant þ
objective task)
Relevant object (financial skills). Objective task
included
Specific function, not generalizable.
MARS (combined discrepancy
questionnaire self/informant þ
self-rating/objective task)
Comprehensive for everyday memory awareness.
Uses isomorphic scales for evaluation and
objective tasks.
Objective testing increases length of time needed.
Memory awareness only.
MARS-A (combined discrepancy
questionnaire self/informant þ
self-rating/objective task)
Comprehensive for everyday memory awareness.
Suitable for longitudinal monitoring of awareness
as condition progresses.
Objective testing increases length of time needed.
Memory awareness only.
Metacognition questionnaire.
(other: self-rating)
Mixed objects. Simple, brief (7 items). Flexible, can
be used with informant rating or objective task.
Validity and administration time may depend on
choice of additional informant ratings or
objective tests used. Screening tool rather than
evaluative measure.
QuENA (discrepancy
questionnaire)
Relevant object (topographical orientation).
Includes risk assessment for getting lost.
Specific function, not generalizable.
SED-11Q (discrepancy
questionnaire)
Mixed objects. Medium length (11 items). Dual
purpose, diagnosis, and awareness assessment.
Dependent on reliability of informant ratings.
Focuses on difficulties or symptoms. Less
suitable for postdiagnostic use.
SIJID (other: combined structured
interview with discrepancy
questionnaire self-rating/
informant)
Mixed objects. Detailed tool for assessing dangerous
behavior and risk, and predicting care needs.
Complicated scoring. Risk assessment rather than
evaluating person’s experience.
Abbreviations: AAQ, Abridged Anosognosia Questionnaire-Dementia; DDS, Dementia Deficits Scale; DQ, Discrepancy Questionnaire; MAFS, Measure of
Awareness of Financial Skills; MARS, Memory Awareness Rating Scale; MARS-A, Memory Awareness Rating Scale-Adjusted; QuENA, Questionnaire for Everyday
Navigational Ability; SED-11Q, Symptoms of Early Dementia-11 Questionnaire; SIJID, Structured Interview for Insight and Judgment in Dementia.
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provision of person-centered care (AwareCare). One well-
established multidomain research measure (AQ-D) has been
abridged as a 9-item clinical tool (Abridged Anosognosia
Questionnaire [AAQ]). Another was designed as a more
detailed tool with predictive capability for risk assessment and
care planning (Structured Interview for Insight and Judgment
in Dementia [SIJID]). One measure can be used with dual
purpose for dementia diagnosis and assessment of awareness
(Symptoms of Early Dementia-11 Questionnaire [SED-11Q]).
Finally, in 5 measures, clinical use is suggested, although it
is not fundamental to the design. This includes 2 related tools
(MARS and Memory Awareness Rating Scale-Adjusted
[MARS-A]) that compare self- and informant ratings with an
objective, ecologically valid measurement of memory function
as well as computing a discrepancy between the self- and infor-
mant ratings. Another tool employs 2 informants to produce 2
discrepancy scores (Dementia Deficits Scale [DDS]). There is
also a medium length D-Q that assesses mixed objects of
awareness, and a brief questionnaire offering a simple, flexible
scale that could be used alongside informant ratings and/or
objective tests (Metacognition Questionnaire).
Discussion
Key Findings
To our knowledge, this is the first scoping review to use sys-
tematic methodology to investigate awareness measures in
PwD and to appraise clinical utility. The review included both
quantitative and qualitative methods and a range of dementia
diagnoses and severity, with most of the research carried out in
Western populations of people with mild-to-moderate AD. The
results show that numerous methods of measuring awareness
have been employed, which may reflect the different aspects of
awareness that have been conceptualized and explored and/or
the lack of an agreed gold standard. The most commonly used
method employs the discrepancy between the person with
dementia and an informant in evaluation of function, with clin-
ician ratings the second most common method. Interestingly,
we found that many methods were not validated and were
frequently designed and used in a single study only. When
established validated measures were employed, they were often
modified (in 28 articles) and consequently were used in a non-
validated way. There were 16 tools used in dementia but devel-
oped in other populations, of which 3 have subsequently been
validated for dementia. There were 30 measures that were
developed and validated for use in dementia populations; only
11 of these have been proposed for clinical use, but there is
little evidence that these tools have been adopted into clinical
practice. The qualitative methods identified in the review
demonstrate how awareness can be elicited and described,
which could perhaps lead to the development of interventions,
but are not directly suitable for a clinical tool. We anticipated
that including case studies would demonstrate how awareness
had been measured in clinical practice; however, we found only
4 case reports that provided detail of how awareness was
assessed.
Addressing the Review Objectives
Characteristics of the measures. The characteristics of the vali-
dated measures can initially be delineated by the type of
method represented. For measures that use discrepancy meth-
ods, reliability depends on the accuracy of each rating type.
Informant ratings are supported in health measures used else-
where, for example,58 and if the informant knows the person
well, they can describe everyday situations and highlight abil-
ities or problems. Not all PwD have a close family member or
carer available to provide this information. While increased
carer burden and/or carer stress has been associated with
impaired awareness,11,59 there are also documented concerns
about accuracy of informant ratings, with more negative ratings
made in the context of carer stress or a difficult relationship
with the person with dementia.6,60-62 Apart from denoting areas
where there is lack of awareness, perhaps indicating a need for
closer supervision, measures of this type might also be useful in
identifying areas of potential disagreement between the dyad,
where sensitive negotiation is required.
Self-ratings by PwD can be influenced by personality, self-
concept, and mood,6,63 which can further reduce the reliability
of the discrepancy methods. However, some studies have
shown ratings by PwD to be more accurate than the informant
evaluation when compared to actual performance.64 Awareness
is an essentially subjective experience, so enabling self-
expression of experiences, as demonstrated in some of the quali-
tative studies,65-68 may be integral to portraying the phenomenon
faithfully. Ideally, this would be in comparison to an objective
marker, such as expressed awareness of diagnosis or condition in
relation to a clinically determined diagnosis of dementia.
There is some evidence that objective performance methods
are more accurate than informant discrepancy methods.69 Per-
formance tasks can sometimes be unrepresentative of everyday
function, and reliability can be influenced by anxiety due to an
unfamiliar task and surroundings. Some of the measures we
reviewed employed everyday tasks to reduce this factor, for
example, rating prior experience and current performance of
remembering a message to deliver, recognizing people or find-
ing one’s way around (MARS), or being able to remember
medication instructions or name and address (Williamson Per-
centile Ranking Method). As the dementia progresses, tasks at
home tend to be performed with more supervision from carers,
so formal assessment under standardized conditions may
become a more typical representation of everyday situations.64
Using a combination of these methods, with self-rated, infor-
mant rated, and objective scores as in MARS, MARS-A, and
MAFS, is likely to improve accuracy of the awareness assess-
ment,8 but may become unwieldy where brevity is required,
such as in a clinical setting.
Clinician ratings can be prone to subjectivity bias, particu-
larly the least structured measures that may depend on clinician
experience, or be influenced by prior knowledge of the
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participant or the strength of the professional relationship.
Some measures provide detail of inter-rater reliability (eg,
Reed) but typically lack other validation data. However, it
should be noted that recommendations for validation criteria
have developed over the years,70 as reflected in the increas-
ingly comprehensive validation data generally provided for the
more recently developed measures, for example, AAQ, SIJID,
and Insight Questionnaire.
The scope of a measure is indicated by the intended aim, for
example, a predictive tool such as SIJID, developed for risk
assessment, could assist in care planning and resource manage-
ment. A discriminative tool, such as the CERAD insight item,
could be used to assist in determining diagnosis of dementia
subtype or offering interventions. Single-item measures tend to
treat lack of awareness as a symptom to be elicited but lack the
amount of detail about individuals that would be needed for
personalized care planning. Dual-purpose tools (eg, SED-11Q)
could assist time management at the diagnostic appointment,
but may be less suitable for a post-diagnostic assessment of
awareness. Some tools are designed for an in-depth evaluation,
which could allow a more tailored response to care discussions
(eg, MARS, MARS-A), but again, the length of assessment
could be a barrier to clinical use.
We would expect a clinical measure to assess awareness of
relevant and specified objects. A range of objects were assessed
in most of the validated measures, including 7 of the potential
clinical tools, although 2 are limited to memory awareness
(MARS, MARS-A). Tools with relevant but specific narrow
aims (MAFS, QuENA) would benefit a specialized assessment,
for example, by an occupational therapist, where these specific
needs had been identified, but not a general assessment. Only
one tool (AwareCare) was specifically designed to assess
awareness in people with severe dementia. This is also the only
tool that uses a purely observational method that is not reliant
on verbal ability of PwD, and the only validated measure that
assesses awareness at the sensory registration level.
In general, the articles in this review did not specify the level
of awareness under consideration,25 although those using DQs
could be described as operating at the evaluative level. Again,
there are few measures with a stated aim to measure meta-
representational awareness, although many measures, includ-
ing clinician ratings, start with a question for the person with
dementia concerning any problems with function or eliciting
the reason for attendance, such as CIRS, ASPIDD, SC-Q, and
guideline for the rating of awareness of cognitive deficits
(GRAD), or how their condition affects others, such as Univer-
sity of California Los Angeles Structured Insight Interview
(UCLA-SII), DDS, and DQ. The use of vignettes explored how
PwD may recognize and interpret changes in others with
dementia, without a direct challenge to personal identity. Stud-
ies using mixed methods71 have shown how illness representa-
tions could be used to enhance communication by mirroring the
language used by the person with dementia, regarding illness,
to explore awareness of identity and cause of condition. It
would be interesting to see if these approaches could be incor-
porated into a quantitative measure of awareness.
Awareness can be assessed at the level of performance
(online) monitoring, and research has demonstrated the contri-
bution of this aspect of awareness to overall functioning, using
error detection methods, for example.72-74 Although these
metamemory studies, as well as some naturalistic studies64,69,75
investigate error responses and/or evaluation of performance
after a test, only a few validated measures of awareness incor-
porate this approach, such as MARS, MAFS, and CMT. Online
monitoring of performance is an ability that could be targeted
in goal-orientated cognitive rehabilitation programs,76 and test-
ing awareness at this level would be a useful component of a
clinical tool to direct interventions.
The review showed that the commonly used terms were
anosognosia, insight (or lack of), and awareness, but also found
the use of “self-consciousness” and “self-awareness” as addi-
tional, broader descriptions of the awareness phenomena,
incorporating self-concept with awareness of mental, physical,
social, and moral matters.77-80 Different awareness terms were
often used interchangeably, suggesting that the terms them-
selves may have little value in distinguishing between phenom-
ena examined, unless clearly defined. Research has
demonstrated that awareness is a complex nonunitary phenom-
enon,17,22,23,37 and applying the levels and objects framework,
it is clear that the validated measures do not all assess the same
aspect or aspects of awareness, which leads to difficulties in
making direct comparisons. Different processes are considered,
for example, in acknowledging difficulties either with general
memory (Memory discrepancy rating, Reed) or with specific
tasks such as managing money and writing cheques (DQ,
AQ-D, AAQ, MAFS); these are distinct from assessing aware-
ness of actual performance in these areas (MAFS, MARS), and
something different from a global assessment of awareness of
having a brain condition or memory problem (UCLA SII,
GRAD).
Clinical utility. A comparison of the clinical utility of the vali-
dated measures is problematic as there is currently no clear
evidence of which phenomena would be most useful to mea-
sure in a clinical setting. Studies that have used awareness
measures to select or assess interventions,81-85 or assist in diag-
nosis,86,87 or to explore awareness in the context of capacity to
make treatment decisions18 have used a range of different mea-
sures, but there are insufficient clinical studies to provide a
direct comparison of methods. The area of capacity to make
decisions offers wide-ranging applications in clinical care, for
example, regarding decisions about medication, further medi-
cal investigations and procedures,18-20,88 as well as social
issues such as appointing power of attorney or making choices
about hospital admission or care placement. Identifying the
most appropriate way to measure awareness to inform capacity
assessments would be valuable. Further studies may be
required to ascertain precisely which phenomena and hence
what kind of tool would be useful for these clinical purposes.
For simplicity, we can speculate which features would be
beneficial. For ease of use in a clinic, DQ measures are likely to
be the simplest and quickest to administer, with reasonable
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training requirements for staff. The AAQ is the shortest of
these, with 9 items. The optimal length of an assessment would
be determined by the specific setting and use of a tool, with
different requirements, for example, in an emergency assess-
ment of needs, or a planned assessment for choosing activities
or interventions. Single-item measures vary in brevity. Some,
with limited complexity, use the response to a single question
or a few questions, such as the CAMDEX awareness item.
Others use information from a combination of sources, for
example, Inaccurate Insight item, and could be incorporated
into an in-depth assessment, but would be too lengthy to be
used in a brief tool. Most of the validated questionnaire
measures use an uncomplicated scoring method using a scale,
a feature which would be suitable for evaluation of needs and
monitoring of outcomes in a clinical context.
Considering accessibility to PwD, some validated measures
require comparison of current ability to ability 5 years ago or
ability 10 years ago (Memory Questionnaire and AII, respec-
tively). This cognitively complex task could be difficult in the
context of impaired memory function, although does poten-
tially interrogate the awareness of change over time. A com-
parison of ability with an average person of the same age has
also been used (Williamson Percentile Ranking Method). This
concept may also be difficult for PwD to grasp, as found in the
original MARS scale that was later amended to drop the
“averageness” score.89 Use of diagrams to indicate self-rated
ability (eg, bell curve in Williamson Percentile Ranking
Method) could be challenging if visuospatial function is
impaired and for dementia diagnoses with primarily visual def-
icits such as posterior cortical atrophy, but may be more suit-
able where there is language impairment such as in semantic
dementia.
Person-centered care90,91 embodies the views of PwD at the
center of decision-making, considering their individuality and
seeking their perspective where possible. This should lead to a
flexible approach to care that respects personal preferences and
individual circumstances and relationships and is recom-
mended in national and international guidelines.92,93 The ter-
minology used in some of the tools reflects their origins in a
disease or deficit-orientated model rather than a person-
centered approach, which may restrict the depth of personal
information shared by the person with dementia. An interroga-
tive style that describes a scenario and encourages the partici-
pant to describe how they think they might manage in that
situation could collect information that is perhaps more authen-
tic and different from a questionnaire that asks direct questions
about the presence or absence of problems or deficits. Balan-
cing the negative items that rate difficulties with the positive
items that rate abilities could encourage highly aware PwD to
report personal strengths and adaptations as well as perceived
weaknesses. Using shared language when describing dementia
has been shown to be helpful,3 that is, finding out and using the
term that the person uses to describe their condition, for exam-
ple “memory problems,” “being forgetful,” or a diagnostic
label such as “Alzheimer’s,” and this could be effective when
measuring awareness clinically. Although a relatively new
advancement, involving PwD and carers in the development
of tools, is likely to help in this regard.
Implications
Although there is an array of tools for measuring awareness,
there are relatively few designed for clinical use and few stud-
ies in a clinical context. Considering the broad range of clinical
areas where an awareness assessment would be valuable, it is
conceivable that the requirements would not be satisfied by a
single tool. Therefore, choice of tool should be governed by the
task requirements, but we would anticipate the tool would
include the features of relevant objects, brevity, and develop-
ment in consultation with PwD. Awareness is most pertinent to
the care of PwD where it influences well-being and autonomy.
These areas can be summarized as (1) where impaired aware-
ness of difficulties has serious safety implications, (2) where
awareness of difficulties or prognosis leads to anxiety and low
mood, (3) where impaired awareness of abilities results in
unnecessary restriction, and (4) where the mismatch in percep-
tion of ability between PwD and carers causes friction and
stress. The available tools for clinical use tend to focus on
the first issue, and recent developments include validated tools
for risk assessment (SIJID) and for diagnosing lack of aware-
ness (AAQ).
A finding of the review suggests that further investigation of
clinical uses of measuring awareness would be informative. A
new clinical tool for use in mild-to-moderate dementia, which
uses a person-centered approach to elicit and measure aware-
ness would be useful. The tool could build a profile of aware-
ness across different domains, be used in individual care
decisions, and identify areas of tension between PwD and
carers, highlighting where extra support may be needed and
identify areas for intervention. This might benefit from com-
bining methods to improve reliability, with inclusion of a range
of objects relevant to everyday life, while remaining short
enough to be feasible for clinical use. The involvement of PwD
and their carers in tool development would help ensure that a
new tool is sensitive to the needs of PwD and the views of their
advocates.
Models of care for PwD now focus on facilitating “living
well” and maintaining independence where possible, recogniz-
ing individuality and encouraging self-involvement in deci-
sions about care and activity where achievable.94 A new
clinical tool could help understand the lived experience of
those living with dementia and to offer appropriate support in
health care decisions, activity planning and care need provision
as well as supporting carers, and signposting suitable
interventions.
Strengths and Limitations
The scoping review framework allowed a broad scope, includ-
ing studies employing different methodologies, and a range of
types and severity of dementia. It also allowed flexibility in
data extraction and analysis. The search was performed
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systematically, in line with a previously published protocol.
The broad range of search terms resulted in a large number
of articles included in the review. In keeping with scoping
review guidance, quality criteria were not applied to the
included articles; however, focusing on validated measures
may have mitigated this to some extent. The psychometric
properties of the validated measures were not fully evaluated,
as this was outside the remit of this review; here we set a low
threshold for describing studies as validated, to allow for a
more inclusive and comprehensive appraisal of measures. A
follow-on study could usefully employ systematic review
methodology to review the selected validated measures in more
detail.
Gaps in Research
The articles in this review are primarily from Western regions
and ethnicity was not consistently reported, though it is
possible that this may have been due to limiting articles to
English-language only. It is unclear whether measures would
be acceptable for use across cultural groups. Few methods
categorized the level of awareness studied and inclusion of
different levels could ensure a wider ranging assessment of
awareness. There are few measures suitable for clinical use that
adopt a person-centered model. Studies using or comparing
tools in clinical settings are lacking. A brief clinical tool with
a person-centered approach would be a useful addition.
Conclusions
Although there are many areas where measuring awareness
could be advantageous, there were few studies that investigated
clinical applications in dementia and there were few tools
designed specifically for clinical purposes. For assessing
awareness in severe dementia, the AwareCare measure offers
a useful observational tool that can be used in care home set-
tings. In earlier stages of dementia when the person is likely to
be living at home, specific functional awareness testing could
include the MAFS to assess awareness of financial manage-
ment skills, and the QuENA could be used to assess the risk of
getting lost. A wider assessment of memory awareness could
include MARS, or the MARS-A, in moderate dementia, which
would be useful to indicate the problems likely to be encoun-
tered due to impaired awareness around everyday memory
function. For a brief assessment of general awareness, use
could be made of the AAQ in a home or hospital setting, or
the Metacognition Questionnaire, which has the advantage of
the flexibility to use different objective tests.
The identified clinical tools available for mild-to-moderate
dementia were designed to measure reduced awareness and
risk. However, there are other areas of care where assessing
awareness could be beneficial. These include identifying peo-
ple who are at higher risk of mood disturbance due to aware-
ness of their condition, or highlighting choices or activities that
are restricted by underestimation of ability by either the PwD or
the carer, as well as revealing tensions between carer and PwD
where views on abilities differ. Currently, there is no brief tool
that evaluates awareness from a person-centered perspective.
This is needed to enhance communication and the effectiveness
of the assessment. Further investigation and development of a
brief person-centered tool could facilitate health and care
choices in mild-to-moderate dementia, targeting the most
appropriate and effective use of resources and optimizing out-
comes for living well with dementia.
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